High materiality7/10
CAPR downgraded to Neutral from Buy at Roth Capital
Why it may matterVerify against the original reporting
Analyst downgrade indicating negative sentiment.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Capricor Therapeutics CAPR downgraded to Neutral from Buy by Roth Capital; target $7; posted price $7.
- Roth Capital downgraded CAPR to Neutral from Buy; target $7.
Key facts
- 01
Target: $7
- 02
Posted price: $7
- 03
Analyst firm: Roth Capital
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.